AAAAAA

   
Results: 1-24 |
Results: 24
Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer
Authors: Lippman, SM Lee, JJ Karp, DD Vokes, EE Benner, SE Goodman, GE Khuri, FR Marks, R Winn, RJ Fry, W Graziano, SL Gandara, DR Okawara, G Woodhouse, CL Williams, B Perez, C Kim, HW Lotan, R Roth, JA Hong, WK
Citation: Sm. Lippman et al., Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer, J NAT CANC, 93(8), 2001, pp. 605-618
Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: A phase II trial of the southwest oncology group
Authors: Kelly, K Lovato, L Bunn, PA Livingston, RB Zangmeister, J Taylor, SA Roychowdhury, D Crowley, JJ Gandara, DR
Citation: K. Kelly et al., Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: A phase II trial of the southwest oncology group, CLIN CANC R, 7(8), 2001, pp. 2325-2329
Neoadjuvant therapy for non-small cell lung cancer
Authors: Gandara, DR Lara, PN Goldberg, Z Roberts, P Lau, DHM
Citation: Dr. Gandara et al., Neoadjuvant therapy for non-small cell lung cancer, ANTI-CANC D, 12, 2001, pp. S5-S9
Gemcitabine in combination with new platinum compounds: An update
Authors: Gandara, DR Edelman, MJ Lara, PN Lau, DHM
Citation: Dr. Gandara et al., Gemcitabine in combination with new platinum compounds: An update, ONCOLOGY-NY, 15(3), 2001, pp. 13-17
Prospective evaluation of cancer clinical trial accrual patterns: Identifying potential barriers to enrollment
Authors: Lara, PN Higdon, R Lim, N Kwan, K Tanaka, M Lau, DHM Wun, T Welborn, J Meyers, FJ Christensen, S O'Donnell, R Richman, C Scudder, SA Tuscano, J Gandara, DR Lam, KS
Citation: Pn. Lara et al., Prospective evaluation of cancer clinical trial accrual patterns: Identifying potential barriers to enrollment, J CL ONCOL, 19(6), 2001, pp. 1728-1733
Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: Sobering results
Authors: Breathnach, OS Freidlin, B Conley, B Green, MR Johnson, DH Gandara, DR O'Connell, M Shepherd, FA Johnson, BE
Citation: Os. Breathnach et al., Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: Sobering results, J CL ONCOL, 19(6), 2001, pp. 1734-1742
Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-celllung cancer: A Southwest Oncology Group trial
Authors: Kelly, K Crowley, J Bunn, PA Presant, CA Grevstad, PK Mainpour, CM Ramsey, SD Wozniak, AJ Weiss, GR Moore, DF Israel, VK Livingston, RB Gandara, DR
Citation: K. Kelly et al., Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-celllung cancer: A Southwest Oncology Group trial, J CL ONCOL, 19(13), 2001, pp. 3210-3218
Activity of high-dose toremifene plus cisplatin in platinum-treated nonsmall-cell lung cancer: a phase II California Cancer Consortium Trial
Authors: Lara, PN Gandara, DR Longmate, J Gumerlock, PH Martin, DHML Edelman, J Gandour-Edwards, R Mack, PC Israel, V Raschko, J Frankel, P Perez, EA Lenz, HJ Doroshow, JH
Citation: Pn. Lara et al., Activity of high-dose toremifene plus cisplatin in platinum-treated nonsmall-cell lung cancer: a phase II California Cancer Consortium Trial, CANC CHEMOT, 48(1), 2001, pp. 22-28
Ten-year follow-up of Southwest Oncology Group 8269: a phase II trial of concomitant cisplatin - etoposide and daily thoracic radiotherapy in limitedsmall-cell lung cancer
Authors: Thomas, CR Giroux, DJ Janaki, LM Turrisi, AT Crowley, JJ Taylor, SA McCracken, JD Giri, PGS Gordon, W Livingston, RB Gandara, DR
Citation: Cr. Thomas et al., Ten-year follow-up of Southwest Oncology Group 8269: a phase II trial of concomitant cisplatin - etoposide and daily thoracic radiotherapy in limitedsmall-cell lung cancer, LUNG CANC, 33(2-3), 2001, pp. 213-219
Dolastatin-10 in metastatic melanoma: A phase II and pharmokinetic trial of the california cancer consortium
Authors: Margolin, K Longmate, J Synold, TW Gandara, DR Weber, J Gonzalez, R Johansen, MJ Newman, R Baratta, T Doroshow, JH
Citation: K. Margolin et al., Dolastatin-10 in metastatic melanoma: A phase II and pharmokinetic trial of the california cancer consortium, INV NEW DR, 19(4), 2001, pp. 335-340
Integration of new chemotherapeutic agents into chemoradiotherapy for stage III non-small cell lung cancer: Focus on docetaxel
Authors: Gandara, DR Lara, PN Goldberg, Z Lau, DHM
Citation: Dr. Gandara et al., Integration of new chemotherapeutic agents into chemoradiotherapy for stage III non-small cell lung cancer: Focus on docetaxel, SEMIN ONCOL, 28(3), 2001, pp. 26-32
Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma - Carboplatin and gemcitabine followed by paclitaxel
Authors: Edelman, MJ Gandara, DR Lau, DHM Lara, P Lauder, IJ Tracy, D
Citation: Mj. Edelman et al., Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma - Carboplatin and gemcitabine followed by paclitaxel, CANCER, 92(1), 2001, pp. 146-152
Control of high-dose-cisplatin-induced emesis with an all-oral three-drug antiemetic regimen
Authors: Hesketh, PJ Roman, A Hesketh, AM Perez, EA Edelman, M Gandara, DR
Citation: Pj. Hesketh et al., Control of high-dose-cisplatin-induced emesis with an all-oral three-drug antiemetic regimen, SUPP CARE C, 8(1), 2000, pp. 46-48
Activity of docetaxel in platinum-treated non-small-cell lung cancer: Results of a phase II multicenter trial
Authors: Gandara, DR Vokes, E Green, M Bonomi, P Devore, R Comis, R Carbone, D Karp, D Belani, C
Citation: Dr. Gandara et al., Activity of docetaxel in platinum-treated non-small-cell lung cancer: Results of a phase II multicenter trial, J CL ONCOL, 18(1), 2000, pp. 131-135
A phase II trial of etoposide, leucovorin, 5-FU, and interferon alpha 2b (ELFI) plus G-CSF for patients with pancreatic adenocarcinoma: a Southwest Oncology Group study (SWOG 9413)
Authors: Macdonald, JS Jacobson, JL Modiano, M Moore, DF Gandara, DR Schroder, LE Chapman, RA
Citation: Js. Macdonald et al., A phase II trial of etoposide, leucovorin, 5-FU, and interferon alpha 2b (ELFI) plus G-CSF for patients with pancreatic adenocarcinoma: a Southwest Oncology Group study (SWOG 9413), INV NEW DR, 18(3), 2000, pp. 269-273
Evaluation of docetaxel in previously untreated extensive-stage small celllung cancer: A Southwest Oncology Group phase II trial
Authors: Hesketh, PJ Crowley, JJ Burris, HA Williamson, SK Balcerzak, SP Peereboom, D Goodwin, JW Gross, HM Moore, DF Livingston, RB Gandara, DR
Citation: Pj. Hesketh et al., Evaluation of docetaxel in previously untreated extensive-stage small celllung cancer: A Southwest Oncology Group phase II trial, CA J SCI AM, 5(4), 1999, pp. 237-241
A phase II evaluation of all-trans-retinoic acid plus interferon alfa-2a in stage IV melanoma: a Southwest Oncology Group Study
Authors: Sondak, VK Liu, PY Flaherty, LE Fletcher, WS Periman, P Gandara, DR Taylor, SA Balcerzak, SP Meyskens, FL
Citation: Vk. Sondak et al., A phase II evaluation of all-trans-retinoic acid plus interferon alfa-2a in stage IV melanoma: a Southwest Oncology Group Study, CA J SCI AM, 5(1), 1999, pp. 41-47
RB status as a determinant of response to UCN-01 in non-small cell lung carcinoma
Authors: Mack, PC Gandara, DR Bowen, C Edelman, MJ Paglieroni, T Schnier, JB Gelmann, EP Gumerlock, PH
Citation: Pc. Mack et al., RB status as a determinant of response to UCN-01 in non-small cell lung carcinoma, CLIN CANC R, 5(9), 1999, pp. 2596-2604
Chemoradiation for locally advanced, unresectable NSCLC - New standard of care, emerging strategies - The Gordon/Vokes article reviewed
Authors: Leigh, BR Gandara, DR
Citation: Br. Leigh et Dr. Gandara, Chemoradiation for locally advanced, unresectable NSCLC - New standard of care, emerging strategies - The Gordon/Vokes article reviewed, ONCOLOGY-NY, 13(8), 1999, pp. 1088
Treatment of poor-prognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - a Southwest Oncology Group clinical and pharmacokinetic study
Authors: Grunberg, SM Crowley, J Hande, KR Giroux, D Munshi, N Lan, DHM Schroder, LE Zangmeister, MH Balcerzak, SP Hynes, HE Gandara, DR
Citation: Sm. Grunberg et al., Treatment of poor-prognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - a Southwest Oncology Group clinical and pharmacokinetic study, CANC CHEMOT, 44(6), 1999, pp. 461-468
Preoperative chemotherapy in stage III non-small cell lung cancer: long-term outcome
Authors: Gandara, DR Leigh, B Vallieres, E Albain, KS
Citation: Dr. Gandara et al., Preoperative chemotherapy in stage III non-small cell lung cancer: long-term outcome, LUNG CANC, 26(1), 1999, pp. 3-6
Emerging role of docetaxel (Taxotere) in advanced non-small cell lung cancer
Authors: Gandara, DR Edelman, MJ Lau, D
Citation: Dr. Gandara et al., Emerging role of docetaxel (Taxotere) in advanced non-small cell lung cancer, SEMIN ONCOL, 26(3), 1999, pp. 3-7
Gemcitabine and carboplatin in combination: An update of phase I and phaseII studies in non-small cell lung cancer
Authors: Langer, CJ Gandara, DR Calvert, P Edelman, MJ Ozols, RF
Citation: Cj. Langer et al., Gemcitabine and carboplatin in combination: An update of phase I and phaseII studies in non-small cell lung cancer, SEMIN ONCOL, 26(1), 1999, pp. 12-18
Serotonergic blockade in the treatment of the cancer anorexia-cachexia syndrome
Authors: Edelman, MJ Gandara, DR Meyers, FJ Ishii, R O'Mahony, M Uhrich, M Lauder, I Houston, J Gietzen, DW
Citation: Mj. Edelman et al., Serotonergic blockade in the treatment of the cancer anorexia-cachexia syndrome, CANCER, 86(4), 1999, pp. 684-688
Risultati: 1-24 |